Acute renal failure in people with cystic fibrosis

Southern, Kevin W

doi:10.1136/thx.2006.072355

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The above-mentioned causes can significantly accelerate the disease-related decline in the glomerular filtration rate. Additionally, treating lung disease in CF may result in toxicity and drug-drug interaction complications, especially with aminoglycosides [25,26]. Renal pathologies in CF patients have been considered rare, but recently, renal problems such as diabetic glomerulopathy, amyloidosis, postinfectious glomerulonephritis, membranous nephropathy, chronic interstitial nephropathy or tubular damage have been observed more and more often [27].…”

Section: Discussionmentioning

confidence: 99%

Renal Function in Patients with Cystic Fibrosis: A Single-Center Study

Rachel

Galiniak

Biesiadecki

et al. 2022

IJERPH

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common incurable autosomal recessive disease affecting the Caucasian population. As the prognosis for life extension of CF patients improves, co-morbidities, including kidney disease, become more common. Identifying those at the highest risk of kidney injury is therefore extremely important. The aim of this study was to evaluate the biomarkers of renal function in 50 CF patients using the estimated glomerular filtration rate (eGFR) based on creatinine and cystatin C equation as well as serum creatinine (sCr), serum cystatin C (CysC), serum urea and urinary neutrophil gelatinase-associated lipocalin (uNGAL) concentrations. sCr, CysC, urea and uNGAL were estimated. eGFR was calculated according to the CKD-EPI formula. CysC was significantly increased, while eGFR was significantly lower in the CF group than in the controls (p < 0.001 and p < 0.01, respectively). There was no significant difference in the sCr, urea and uNGAL concentrations between patients with CF and healthy subjects. For the purpose of our analysis, in order to assess renal function in patients with CF in clinical practice, the concentration of serum CysC and eGFRCKD-EPI should be determined. Patients with CF presented with renal function impairment pictured by increased serum CysC and decreased eGFR values compared to controls. Unchanged uNGAL concentrations suggested preserved tubular function despite aminoglycoside treatment. Further prospective studies are needed to clarify whether kidney impairment observed in the course of CF progresses.

show abstract

Section: Discussionmentioning

confidence: 99%

Renal Function in Patients with Cystic Fibrosis: A Single-Center Study

Rachel

Galiniak

Biesiadecki

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…A secondary finding of this study was that 18.6% of patients presented with an elevated BUN/SCr ratio of >20. CF patients are more prone to salt-wasting and dehydration and have higher rates of kidney stones and AKI [ 29 ]. CF patients presenting with APE frequently have elevated respiratory rates and decreased oral intake, further challenging their hydration status.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin

Muirhead

Lim

Lapidus

et al. 2017

Cureus

View full text Add to dashboard Cite

BackgroundThe risk for acute kidney injury (AKI) has been associated with both tobramycin and vancomycin.ObjectiveTo determine whether the rate of drug therapy-related nephrotoxicity is greater in Cystic Fibrosis (CF) patients receiving concomitant vancomycin and tobramycin than patients receiving either agent alone.MethodsAdult CF patients admitted for acute pulmonary exacerbation (APE) over a seven-year period (2008-2014), who received at least 72 hours of intravenous vancomycin, tobramycin or a combination of the two agents were evaluated for AKI. AKI was defined as a 1.5-fold increase in serum creatinine per RIFLE criteria. One hundred seventy-four hospital encounters from 72 unique patients were assessed in this single-center, cross-sectional study.ResultsAKI outcomes were not statistically different. AKI rates were 19% for vancomycin, 8.7% for tobramycin, and 19.7% for combination cohorts (p = 0.16).ConclusionOur data suggest there is no significant difference in AKI risk when vancomycin and tobramycin combination therapy is used.

show abstract

“…Intensive IV use is not without its drawbacks. As CF survival continues to improve [9,10], increased cumulative exposure to high doses of IV antibiotics could increase the frequency and severity of systemic side-effects, particularly renal failure [11,12]. Since 2005, newer classes of inhaled therapies have been introduced and prescriptions of these have also increased [13].…”

Section: Introductionmentioning

confidence: 99%